Should I buy or sell Candel Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Candel Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CADL shares. View CADL analyst ratings or view top-rated stocks .

What is Candel Therapeutics' stock price target for 2024?

1 brokers have issued 1-year target prices for Candel Therapeutics' shares. Their CADL share price targets range from $11.00 to $11.00. On average, they expect the company's share price to reach $11.00 in the next year. This suggests a possible upside of 106.8% from the stock's current price. View analysts price targets for CADL or view top-rated stocks among Wall Street analysts .

How have CADL shares performed in 2024?

Candel Therapeutics' stock was trading at $1.47 at the beginning of 2024. Since then, CADL stock has increased by 261.9% and is now trading at $5.32. View the best growth stocks for 2024 here .

Are investors shorting Candel Therapeutics?

Candel Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 160,900 shares, an increase of 9.2% from the March 15th total of 147,300 shares. Based on an average daily volume of 3,880,000 shares, the short-interest ratio is presently 0.0 days. Currently, 1.0% of the shares of the stock are sold short. View Candel Therapeutics' Short Interest .

When is Candel Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CADL earnings forecast .

How were Candel Therapeutics' earnings last quarter?

Candel Therapeutics, Inc. (NASDAQ:CADL) released its quarterly earnings data on Thursday, March, 28th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.22.

When did Candel Therapeutics IPO?

Candel Therapeutics (CADL) raised $72 million in an IPO on Tuesday, July 27th 2021. The company issued 9,000,000 shares at a price of $8.00 per share. Jefferies, Credit Suisse, BMO Capital Markets and UBS Investment Bank served as the underwriters for the IPO.

How do I buy shares of Candel Therapeutics?

Shares of CADL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CADL

Candel Therapeutics (CADL) Stock Price, News & Analysis

→ Did you know you can now trade Bitcoin in your regular brokerage account? (From DTI) (Ad)

Free CADL Stock Alerts

$5.31

-0.15 (-2.75%)

(As of 02:45 PM ET)

Compare

Today's Range: $5.12
▼
$5.55
50-Day Range: $1.39
▼
$7.28
52-Week Range: $0.66
▼
$11.40

Volume: 363,429 shs
Average Volume: 4.37 million shs
Market Capitalization: $155.85 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.00

Get Candel Therapeutics alerts:

Candel Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 106.8% Upside
$11.00 Price Target
Short Interest: Healthy
1.03% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.98
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.34 out of 5 stars

Medical Sector

565th out of 918 stocks

Biological Products, Except Diagnostic Industry

88th out of 151 stocks

3.5

Analyst's Opinion

Consensus Rating
Candel Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Candel Therapeutics has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.03% of the float of Candel Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Candel Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Candel Therapeutics has recently increased by 9.23%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Candel Therapeutics does not currently pay a dividend.
Dividend Growth
Candel Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CADL.

3.9

News and Social Media Coverage

News Sentiment
Candel Therapeutics has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Candel Therapeutics this week, compared to 1 article on an average week.
Search Interest
49 people have searched for CADL on MarketBeat in the last 30 days. This is an increase of 4,800% compared to the previous 30 days.
MarketBeat Follows
20 people have added Candel Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 900% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Candel Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
44.60% of the stock of Candel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 13.93% of the stock of Candel Therapeutics is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Candel Therapeutics is -4.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Candel Therapeutics is -4.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Candel Therapeutics has a P/B Ratio of 12.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Candel Therapeutics Stock (NASDAQ:CADL)

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is based in Needham, Massachusetts.

CADL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CADL Stock News Headlines

April 5, 2024 | marketbeat.com

Unusually High Volume Points to Upside in These Stocks

If investing were easy, everybody would do it, and we would all be rich. But that isn't the case.

April 5, 2024 | marketbeat.com

Unusually High Volume Points to Upside in These Stocks

Unusually high volume is often a signal of higher price to come; this is a look at three stocks with recent volume spikes and a reason for the price to advance.

April 19, 2024 | Darwin (Ad)

2024's Must-Have Guide: Master Crypto Investment Today

The cryptocurrency revolution is here with Bitcoin soaring past the $70,000 milestone—a clear indicator of the booming digital currency market. Are you prepared to navigate these exciting yet complex waters? Introducing "Navigating the Future: A Comprehensive Guide to Cryptocurrency Investments in 2024." This free digital guide is your essential resource for understanding and capitalizing on cryptocurrency investments, tailored for both newcomers and seasoned investors. (**By clicking the link you are subscribing to The Conservative Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

April 15, 2024 | seekingalpha.com

Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer

April 11, 2024 | markets.businessinsider.com

Candel Therapeutics' CAN-2409 For Pancreatic Cancer Gets FDA Orphan Drug Designation; Stock Up

April 11, 2024 | markets.businessinsider.com

Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

April 11, 2024 | marketwatch.com

Candel Therapeutics Shares Leap Premarket on FDA Orphan-Drug Designation

April 11, 2024 | globenewswire.com

Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer

April 19, 2024 | Darwin (Ad)

2024's Must-Have Guide: Master Crypto Investment Today

April 9, 2024 | globenewswire.com

Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors

April 6, 2024 | finance.yahoo.com

Retail investors invested in Candel Therapeutics, Inc. (NASDAQ:CADL) up 320% last week, insiders too were rewarded

April 5, 2024 | benzinga.com

What's Going On With Candel Therapeutics Stock On Friday?

April 5, 2024 | msn.com

Candel Therapeutics stock jumps as pancreatic cancer treatment shows promise

April 4, 2024 | msn.com

Why Allurion Technologies Stock Is Racing Higher

April 4, 2024 | investing.com

After-hours movers: SoFi Technologies, GameStop, and more

April 4, 2024 | marketwatch.com

Candel Therapeutics Shares Hit 52-Week High After Positive Trial Data

April 4, 2024 | markets.businessinsider.com

Candel's CAN-2409 Shows Positive Trial Results In Non-Metastatic Pancreatic Cancer; Stock Up

April 4, 2024 | finance.yahoo.com

After Brain Cancer Data, Candel Therapeutics' Shares Good News From Pancreatic Cancer Study

April 4, 2024 | globenewswire.com

Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

April 1, 2024 | msn.com

Micro-Cap Cancer Focused Candel Therapeutics Highlights Encouraging Data From Brain Tumor Immunotherapy

March 28, 2024 | globenewswire.com

Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma

March 28, 2024 | investorplace.com

CADL Stock Earnings: Candel Therapeutics Misses EPS for Q4 2023

March 28, 2024 | benzinga.com

Recap: Candel Therapeutics Q4 Earnings

March 28, 2024 | globenewswire.com

Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights

March 5, 2024 | globenewswire.com

Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate

February 21, 2024 | benzinga.com

Candel Therapeutics Stock (NASDAQ:CADL), Short Interest Report

February 13, 2024 | markets.businessinsider.com

Candel's Can-3110 Receives FDA Fast Track Designation

See More Headlines

Receive CADL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Candel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/28/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:CADL
CUSIP: N/A
CIK: 1841387
Web: www.candeltx.com
Phone: 617-916-5445
Fax: N/A
Employees: 42
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $11.00
High Stock Price Target: $11.00
Low Stock Price Target: $11.00
Potential Upside/Downside: +106.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.30)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-37,940,000.00
Net Margins: N/A
Pretax Margin: -102,990.34%
Return on Equity: -142.91%
Return on Assets: -69.87%

Debt

Debt-to-Equity Ratio: 0.97
Current Ratio: 2.59
Quick Ratio: 2.59

Sales & Book Value

Annual Sales: $120,000.00
Price / Sales: 1,301.18
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.44 per share
Price / Book: 12.09

Miscellaneous

Outstanding Shares: 29,350,000
Free Float: 16,258,000
Market Cap: $156.14 million
Optionable: Optionable
Beta: 0.92

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Paul-Peter Tak FMEDSCI (Age 63)
M.D., Ph.D., President, CEO & Director
Comp: $1.16M
Dr. Estuardo Aguilar-Cordova Inf. (Age 65)
M.D., Ph.D., Founder & Director
Comp: $35.08k
Dr. Seshu Tyagarajan Ph.D. (Age 57)
Chief Technical & Development Officer
Comp: $335.27k
Dr. Francesca Barone M.D. (Age 46)
Ph.D., Chief Scientific Officer
Comp: $518.91k
Mr. Charles Schoch (Age 39)
Interim CFO, VP of Finance & Corporate Controller
Ms. Ileen B. Winick
Chief People Officer
Ms. Susan Stewart J.D. (Age 62)
L.L.M., Chief Regulatory Officer
Dr. William Garrett Nichols M.D. (Age 55)
M.S., Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CADL Stock Analysis - Frequently Asked Questions

Should I buy or sell Candel Therapeutics stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Candel Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CADL shares.
View CADL analyst ratings or view top-rated stocks.
What is Candel Therapeutics' stock price target for 2024?: 1 brokers have issued 1-year target prices for Candel Therapeutics' shares. Their CADL share price targets range from $11.00 to $11.00. On average, they expect the company's share price to reach $11.00 in the next year. This suggests a possible upside of 106.8% from the stock's current price.
View analysts price targets for CADL or view top-rated stocks among Wall Street analysts.
How have CADL shares performed in 2024?: Candel Therapeutics' stock was trading at $1.47 at the beginning of 2024. Since then, CADL stock has increased by 261.9% and is now trading at $5.32.
View the best growth stocks for 2024 here.
Are investors shorting Candel Therapeutics?: Candel Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 160,900 shares, an increase of 9.2% from the March 15th total of 147,300 shares. Based on an average daily volume of 3,880,000 shares, the short-interest ratio is presently 0.0 days. Currently, 1.0% of the shares of the stock are sold short.
View Candel Therapeutics' Short Interest.

When is Candel Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our CADL earnings forecast.
How were Candel Therapeutics' earnings last quarter?: Candel Therapeutics, Inc. (NASDAQ:CADL) released its quarterly earnings data on Thursday, March, 28th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.22.
When did Candel Therapeutics IPO?: Candel Therapeutics (CADL) raised $72 million in an IPO on Tuesday, July 27th 2021. The company issued 9,000,000 shares at a price of $8.00 per share. Jefferies, Credit Suisse, BMO Capital Markets and UBS Investment Bank served as the underwriters for the IPO.
How do I buy shares of Candel Therapeutics?: Shares of CADL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CADL) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial